Clinical trials: Gout Chronic
Gout Chronic
Maintenance or Withdrawal of Urate Lowering Therapy According to Ultrasound Features in Gout Patients: a Randomised Controlled Trial Stop Treatment In Gout
According to international recommendations, urate lowering therapy (ULT), mainly the xanthine oxidase inhibitors (XOIs) allopurinol and febuxostat, should be prescribed lifelong in gout patients.
- Trial name
- STING (NCT06956885)
- Testing
- Discontibuation of oral ULT, Maintenance of ULT
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gout
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating…
- Trial name
- NCT00819585
- Testing
- Canakinumab, Colchicine, Allopurinol
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Infection, Heart Failure
Serum Potassium Prediction Using Machine Learning and Single-lead ECG
This is a retrospective study drawing on data from the Brigham and Women's Hospital Home Hospital Program's Database. Sociodemographic and clinical data from a training cohort were used to train a machine learning algorithm to…
- Conditions
- Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT07493798
- Testing
- Potassium estimation algorithm
- Where
- 2 sites in United States
- Sponsor
- Brigham and Women's Hospital
Chronic Gout
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo.
- Trial name
- DISSOLVE II (NCT04596540)
- Testing
- SEL-212 low-dose, SEL-212 high-dose
- Where
- 53 sites in United States, Georgia and 3 more
- Volunteers
- 153 people
- Sponsor
- Swedish Orphan Biovitrum
Chronic Gout
Rasburicase Treatment in Chronic Gouty Arthritis
The study will establish efficacy and safety of rasburicase in chronic gouty arthritis
- Trial name
- NCT05312268
- Testing
- Rasburicase
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Infections, Heart Failure
Rural Hospital-Level Care at Home for Acutely Ill Adults
This study examines the implications of providing hospital-level care in rural homes.
- Conditions
- Infections, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT05256303
- Testing
- Home Hospital care, Traditional Hospital care
- Where
- 3 sites in United States, Canada
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
Gout Flare
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
- Trial name
- NCT04069325
- Testing
- simiaowan, febuxostat
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Chronic Gout
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm trials to determine the safety and efficacy of two different dose levels of SEL-212 compared to placebo.
- Trial name
- DISSOLVE I (NCT04513366)
- Testing
- SEL-212 low-dose, SEL-212 high-dose, Normal Saline
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Swedish Orphan Biovitrum
Gout, Chronic Kidney Diseases
Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study
The aim of this study is to determine the feasibility of running a phase III double-blind, double-dummy randomised controlled trial comparing Depo-Medrone 120mg intramuscular injection vs.
- Trial name
- ASGARD (NCT02578394)
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Mid and South Essex NHS Foundation Trust
Diabetes Mellitus, Hypertension
Evidence-based Laboratory Test Order Sets in Primary Care
Cluster randomised controlled trial to evaluate what the effect is of evidence-based order sets aimed at five indications on the appropriateness of laboratory test ordering in primary care.
- Conditions
- Diabetes Mellitus, Hypertension, Cardiovascular Diseases, Fatigue
- Trial name
- NCT02950142
- Testing
- CPOE with order sets for lab testing, CPOE without order sets for lab testing
- Where
- Belgium
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- OCES-2 (NCT06694012)
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Osaka Metropolitan University
Chronic Pain, Fibromyalgia
Effects of Fasting on Self Efficacy
The study aims to investigate if a 7 day therapeutic fasting regimen will affect self-efficacy of patients with chronic diseases the effects of fasting on physical and mental well-being, quality of life and body awareness/image…
- Conditions
- Chronic Pain, Fibromyalgia, Rheumatoid Arthritis, Gout
- Trial name
- TheraFast (NCT02113111)
- Testing
- Fasting
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universität Duisburg-Essen
Hyperuricemia, Gout
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia in an inpatient, controlled setting.
- Conditions
- Hyperuricemia, Gout, Chronic Kidney Diseases
- Trial name
- NCT04987242
- Testing
- ALLN-346
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Infection, Heart Failure
Home Hospital for Suddenly Ill Adults
The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be…
- Conditions
- Infection, Heart Failure, COPD, Asthma
- Trial name
- NCT03524222
- Testing
- Home Hospitalization
- Where
- 2 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Brigham and Women's Hospital
Chronic Gout Refractory to Conventional Therapy
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
The purpose of the study is to evaluate the safety and clinical effect of re-exposure to a 24 week course of treatment of pegloticase i.v. in subjects whose last exposure to pegloticase i.v.
- Trial name
- NCT00675103
- Testing
- pegloticase 8 mg i.v.
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Savient Pharmaceuticals
Gout, Acute Gout Flare
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and…
- Conditions
- Gout, Acute Gout Flare, Gout Flares
- Trial name
- ABP-745 (NCT06258213)
- Testing
- ABP-745
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd